{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:13:31Z","timestamp":1790712811483,"version":"4.1.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Exposure to cortisol excess in Cushing\u2019s disease (CD) results in increased cardiovascular morbidity and reduces survival, with cardiovascular disease being a leading cause of death. At diagnosis, a significant number of patients have adverse cardiovascular profiles (e.g., obesity, diabetes or impaired glucose tolerance, dyslipidemia, hypertension, cardiac abnormalities and vascular disease). Remission of hypercortisolemia reduces but does not completely eliminate the cardiovascular complications; hazard ratios for myocardial infarction and stroke are high during long-term monitoring, highlighting the long-lasting effects of hypercortisolism and the importance of the timely diagnosis and successful management of this condition. Data on mortality of patients in remission are not consistent but in a multicenter study, an increased all-cause and circulatory mortality in patients with CD in remission for at least 10\u00a0years has been demonstrated. Cardiovascular morbidity requires particular focus and effective management during the care of patients with CD, from their presentation until long-term follow up.<\/jats:p>","DOI":"10.1007\/s11102-022-01258-4","type":"journal-article","created":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T17:09:41Z","timestamp":1658509781000},"page":"750-753","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Cardiovascular health and mortality in Cushing\u2019s disease"],"prefix":"10.1007","volume":"25","author":[{"given":"Amy","family":"Coulden","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross","family":"Hamblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Wass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4696-0643","authenticated-orcid":false,"given":"Niki","family":"Karavitaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"issue":"5","key":"1258_CR1","doi-asserted-by":"publisher","first-page":"R207","DOI":"10.1530\/EJE-20-1309","volume":"184","author":"EV Varlamov","year":"2021","unstructured":"Varlamov EV et al (2021) Management of endocrine disease: cardiovascular risk assessment, thromboembolism, and infection prevention in Cushing\u2019s syndrome: a practical approach. Eur J Endocrinol 184(5):R207\u2013R224","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"1258_CR2","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1210\/jc.2011-2957","volume":"97","author":"ZK Hassan-Smith","year":"2012","unstructured":"Hassan-Smith ZK et al (2012) Outcome of Cushing\u2019s disease following transsphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab 97(4):1194\u20131201","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1258_CR3","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2265.2010.03829.x","volume":"73","author":"EB Geer","year":"2010","unstructured":"Geer EB et al (2010) MRI assessment of lean and adipose tissue distribution in female patients with Cushing\u2019s disease. Clin Endocrinol (Oxf) 73(4):469\u2013475","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"1258_CR4","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1210\/jc.2011-3123","volume":"97","author":"EB Geer","year":"2012","unstructured":"Geer EB et al (2012) Body composition and cardiovascular risk markers after remission of Cushing\u2019s disease: a prospective study using whole-body MRI. J Clin Endocrinol Metab 97(5):1702\u20131711","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"1258_CR5","first-page":"2664","volume":"84","author":"A Colao","year":"1999","unstructured":"Colao A et al (1999) Persistence of increased cardiovascular risk in patients with Cushing\u2019s disease after five years of successful cure. J Clin Endocrinol Metab 84(8):2664\u20132672","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1258_CR6","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1365-2265.2011.04055.x","volume":"75","author":"R Giordano","year":"2011","unstructured":"Giordano R et al (2011) Metabolic and cardiovascular outcomes in patients with Cushing\u2019s syndrome of different aetiologies during active disease and 1 year after remission. Clin Endocrinol (Oxf) 75(3):354\u2013360","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"6","key":"1258_CR7","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1210\/jc.2002-021558","volume":"88","author":"A Faggiano","year":"2003","unstructured":"Faggiano A et al (2003) Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing\u2019s disease during active disease and 1 year after disease remission. J Clin Endocrinol Metab 88(6):2527\u20132533","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1258_CR8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1530\/EJE-13-0569","volume":"169","author":"G Ntali","year":"2013","unstructured":"Ntali G et al (2013) Mortality in Cushing\u2019s syndrome: systematic analysis of a large series with prolonged follow-up. Eur J Endocrinol 169(5):715\u2013723","journal-title":"Eur J Endocrinol"},{"issue":"Suppl 1","key":"1258_CR9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1159\/000314213","volume":"92","author":"G Arnaldi","year":"2010","unstructured":"Arnaldi G et al (2010) Pathophysiology of dyslipidemia in Cushing\u2019s syndrome. Neuroendocrinology 92(Suppl 1):86\u201390","journal-title":"Neuroendocrinology"},{"issue":"Suppl 1","key":"1258_CR10","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1159\/000314315","volume":"92","author":"MV Cicala","year":"2010","unstructured":"Cicala MV, Mantero F (2010) Hypertension in Cushing\u2019s syndrome: from pathogenesis to treatment. Neuroendocrinology 92(Suppl 1):44\u201349","journal-title":"Neuroendocrinology"},{"issue":"3","key":"1258_CR11","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1111\/j.1365-2265.2011.04206.x","volume":"76","author":"PM Toja","year":"2012","unstructured":"Toja PM et al (2012) Clinical relevance of cardiac structure and function abnormalities in patients with Cushing\u2019s syndrome before and after cure. Clin Endocrinol (Oxf) 76(3):332\u2013338","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"11","key":"1258_CR12","doi-asserted-by":"publisher","first-page":"E2144","DOI":"10.1210\/jc.2014-1783","volume":"99","author":"P Kamenicky","year":"2014","unstructured":"Kamenicky P et al (2014) Cardiac structure and function in Cushing\u2019s syndrome: a cardiac magnetic resonance imaging study. J Clin Endocrinol Metab 99(11):E2144\u2013E2153","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1258_CR13","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1210\/jc.2012-3582","volume":"98","author":"OM Dekkers","year":"2013","unstructured":"Dekkers OM et al (2013) Multisystem morbidity and mortality in Cushing\u2019s syndrome: a cohort study. J Clin Endocrinol Metab 98(6):2277\u20132284","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1258_CR14","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S2213-8587(16)30005-5","volume":"4","author":"RN Clayton","year":"2016","unstructured":"Clayton RN et al (2016) Mortality in patients with Cushing\u2019s disease more than 10 years after remission: a multicentre, multinational, retrospective cohort study. Lancet Diabetes Endocrinol 4(7):569\u2013576","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"1258_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2021.101521","volume":"35","author":"OA Hakami","year":"2021","unstructured":"Hakami OA, Ahmed S, Karavitaki N (2021) Epidemiology and mortality of Cushing\u2019s syndrome. Best Pract Res Clin Endocrinol Metab 35(1):101521","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"6","key":"1258_CR16","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1210\/jc.2018-02524","volume":"104","author":"O Ragnarsson","year":"2019","unstructured":"Ragnarsson O et al (2019) Overall and disease-Specific mortality in patients with Cushing disease: a swedish nationwide study. J Clin Endocrinol Metab 104(6):2375\u20132384","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1258_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847\u2013875","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01258-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-022-01258-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-022-01258-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T21:55:19Z","timestamp":1700862919000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-022-01258-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1258"],"URL":"https:\/\/doi.org\/10.1007\/s11102-022-01258-4","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"assertion":[{"value":"8 July 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RH has received a conference grant from Recordati Rare Diseases UK Ltd. NK has received honoraria from Pfizer, Ipsen, HRA Pharma and Recordati Rare Diseases for lectures, research funding from Pfizer, Ipsen and Shire and has served as a member in Scientific Advisory Boards for Pfizer, Ipsen, Recordati Rare Diseases.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}